SCT-200 is under clinical development by SinoCelltech Group and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC). According to GlobalData, Phase II drugs for Esophageal Squamous Cell Carcinoma (ESCC) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SCT-200’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SCT-200 overview

SCT-200 is under development for the treatment of metastatic colorectal cancer, metastatic triple negative breast cancer, esophageal squamous cell carcinoma,  squamous non-small cell lung cancer and recurrent head and neck cancer squamous cell carcinoma. It is administered through intravenous route. The drug candidate is a monoclonal antibody. It acts by targeting the epidermal growth factor receptor (EGFR).

It was under development for the treatment of lymphoma, solid tumors including gastric cancer/gastroesophageal junction cancer, hepatocellular carcinoma, pancreatic cancer, bile duct/gallbladder cancer, renal cell carcinoma and ovarian cancer

SinoCelltech Group overview

SinoCelltech Group (SinoCelltech), formerly Beijing Shenzhou Cell Biotechnology Group, is a biopharmaceutical company that discovers, develops monoclonal antibodies, vaccines and recombinant proteins for treatment of cancer, psoriasis and rheumatoid arthritis. SinoCelltech’s pipeline products comprise of SCT200, a human EGFR monoclonal antibody for colorectal cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma and other solid tumors; SCT400, a human-mouse chimeric anti-CD20 monoclonal antibody indicated for non-Hodgkin’s lymphoma; SCT510, a biosimilar of bevacizumab developed for the treatment of non-small cell lung cancer and colorectal cancer; SCT-I10A, a humanized anti-PD-1 IgG4 monoclonal antibody indicated for esophageal squamous cell carcinoma, gastric adenocarcinoma. The company is also evaluating drug candidates targeting for treatment of psoriasis, rheumatoid arthritis and ankylosing spondylitis. SinoCelltech is headquartered in Beijing, China.

For a complete picture of SCT-200’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.